Novogene Co

Novogene Co Tax Expense

The Income Tax Expense of Novogene Co (688315.SS) as of Nov 4, 2026 is 21.43 M CNY. In the previous year, Income Tax Expense was 20.89 M CNY — a change of 2.57% (higher).

Tax Expense

21.43 MCNY

YoY

2.57%

Last updated:

Income Tax Expense of Novogene Co is 2025 21.43 M CNY. Income Tax Expense of Novogene Co was 2024 20.89 M CNY. It decreases by 2.57% higher compared to the previous year.

The Novogene Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
15.00 M CNY
Jan 1, 2019
4.78 M CNY
Jan 1, 2020
1.09 M CNY
Jan 1, 2021
17.58 M CNY
Jan 1, 2022
27.02 M CNY
Jan 1, 2023
29.41 M CNY
Jan 1, 2024
20.89 M CNY
Jan 1, 2025
21.43 M CNY
The Novogene Co Tax Expense history
YEARTax ExpenseYoY
21.43 MCNY+2.57%
20.89 MCNY-28.96%
29.41 MCNY+8.83%
27.02 MCNY+53.75%
17.58 MCNY+1,513.04%
1.09 MCNY-77.21%
4.78 MCNY-68.12%
15.00 MCNY+92.03%
7.81 MCNY-25.46%
10.48 MCNY+18.89%
8.81 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Novogene Co Stock analysis

What does Novogene Co do? Novogene Co., Ltd. generates revenue through genomic services and solutions, primarily utilizing high-throughput sequencing and bioinformatics analysis technologies. The company offers life science basic research services, medical research and technical services, and database-building sequencing platform services, targeting both domestic and international markets. Key products include gene mutation detection kits, coronavirus disease nucleic acid test services, and DA8600 sequencers, which are sold to research institutions, medical facilities, and clinical applications. The firm's technology-driven approach enables it to provide multi-level scientific and research technical services across life science and medical fields. Novogene's revenue streams are anchored in its sequencing platforms and equipment, with the DA8600 sequencers representing a significant product line. The company develops and sells genetic testing medical equipment, leveraging its expertise in gene sequencing. Its services are tailored for life science basic research, medical and clinical applications, and database construction, serving a diverse clientele including research organizations and healthcare providers. The firm's focus on multi-omics research technology enhances its ability to deliver comprehensive solutions. The business model integrates high-throughput sequencing technology with bioinformatics analysis to create scalable services. Novogene's offerings span from basic research support to clinical diagnostic tools, with gene mutation detection kits and coronavirus disease nucleic acid test services catering to specific market needs. The company's domestic and overseas market presence ensures broad client reach, while its independent development of sequencing equipment like the DA8600 sequencers drives product-based revenue. This dual focus on services and equipment positions Novogene as a key player in genomic technology solutions. Novogene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novogene Co stock

Income Tax Expense of Novogene Co is 21.43 M CNY in 2025.

Income Tax Expense of Novogene Co changed from 20.89 M CNY to 21.43 M CNY, representing a 2.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Novogene Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Novogene Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Novogene Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Novogene Co